Drilldown: Medicines
Medicines > onset 
:
Over weeks or
Postprandial glucose effect within days; HbA1c by 12 weeks or
Seconds
:
Over weeks or
Postprandial glucose effect within days; HbA1c by 12 weeks or
Seconds Use the filters below to narrow your results.
generic:
brand:
classes:
mechanism:
None (1) ·
5-MeO-DMT is a potent 5-HT1A agonist (greater than 5-HT2A). Distinct from N,N-DMT in producing a more unitive, less visual, often ego-dissolving experience. (1) ·
Humanized IgG2 monoclonal antibody binding both isoforms of CGRP peptide (1) ·
Humanized IgG4 monoclonal antibody binding CGRP peptide; prevents CGRP from activating its receptor (1) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)
uses:
starting dose:
None (1) ·
100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) ·
225 mg SC monthly, or 675 mg SC every 3 months (quarterly) (1) ·
5 mg PO once daily (no renal dose adjustment, unlike sitagliptin) (1) ·
Migraine: 240 mg SC loading dose, then 120 mg SC monthly. Cluster: 300 mg SC at onset of cluster period, then monthly during cluster. (1)
preparations:
120 mg/mL prefilled syringe or autoinjector (1) ·
225 mg/1.5 mL prefilled syringe or autoinjector (1) ·
25, 50, 100 mg tablets; combination tablets with metformin (1) ·
5 mg tablets; combination with metformin (1) ·
Parotid-gland venom expressed onto a glass plate, dried into a shellac-like resin, vaporized and inhaled (1)
fda max:
routes:
onset: (Click arrow to add another value)
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 5 results in range #1 to #5.